Literature DB >> 25600201

In Vitro Evaluation of Reversible and Time-Dependent Inhibitory Effects of Kalanchoe crenata on CYP2C19 and CYP3A4 Activities.

Charles Awortwe1, Vamshi K Manda, Cristina Avonto, Shabana I Khan, Ikhlas A Khan, Larry A Walker, Patrick J Bouic, Bernd Rosenkranz.   

Abstract

Kalanchoe crenata popularly known as "dog's liver" is used in most African countries for the treatment of chronic diseases such as diabetes, asthma and HIV/AIDS related infections. The evaluation of K. crenata for herb-drug interactions has not been reported. This study therefore aims to evaluate the risk of K. crenata for herb-drug interaction in vitro. Crude methanol and fractions of K. crenata were incubated and preincubated with recombinant human CYP2C19 and CYP3A4. Comparative studies were conducted in both human liver microsomes and recombinant human CYP to ascertain the inhibition profile of the crude extract and the various fractions. The cocktail approach of recombinant human CYPs was conducted to confirm the inhibition potential of the fractions in the presence of other CYPs. The results showed significant time-dependent inhibition of tested samples on CYP3A4 with crude methanol (39KC), fractions 45A, 45B and 45D given IC50 fold decrease of 3.29, 2.26, 1.91 and 1.49, respective. Time dependent kinetic assessment of 39KC and 45D showed KI and kinact values for 39KC as 1.77 µg/mL and 0.091 min(-1) while that of 45D were 6.45 µg/mL and 0.024 min(-1), respectively. Determination of kinact based on IC50 calculations yielded 0.015 and 0.04 min(-1) for 39KC and 45D, respectively. Cocktail approach exhibited fold decreases in IC50 for all test fractions on CYP3A4 within the ranges of 2.10 - 4.10. At least one phytoconstituent in the crude methanol extract of Kalanchoe crenata is a reversible and time-dependent inhibitor of CYP3A4.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25600201      PMCID: PMC5656046          DOI: 10.2174/1872312809666150119110200

Source DB:  PubMed          Journal:  Drug Metab Lett        ISSN: 1872-3128


  28 in total

1.  Automated high throughput human CYP isoform activity assay using SPE-LC/MS method: application in CYP inhibition evaluation.

Authors:  H Yin; J Racha; S Y Li; N Olejnik; H Satoh; D Moore
Journal:  Xenobiotica       Date:  2000-02       Impact factor: 1.908

Review 2.  Pharmacokinetic interactions between herbal remedies and medicinal drugs.

Authors:  C Ioannides
Journal:  Xenobiotica       Date:  2002-06       Impact factor: 1.908

3.  The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.

Authors:  Thorir D Bjornsson; John T Callaghan; Heidi J Einolf; Volker Fischer; Lawrence Gan; Scott Grimm; John Kao; S Peter King; Gerald Miwa; Lan Ni; Gondi Kumar; James McLeod; R Scott Obach; Stanley Roberts; Amy Roe; Anita Shah; Fred Snikeris; John T Sullivan; Donald Tweedie; Jose M Vega; John Walsh; Steven A Wrighton
Journal:  Drug Metab Dispos       Date:  2003-07       Impact factor: 3.922

4.  Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis.

Authors:  Anthony Atkinson; Jane R Kenny; Ken Grime
Journal:  Drug Metab Dispos       Date:  2005-07-27       Impact factor: 3.922

5.  Cocktail-substrate approach-based high-throughput assay for evaluation of direct and time-dependent inhibition of multiple cytochrome P450 isoforms.

Authors:  Kazumasa Kozakai; Yasuhiro Yamada; Motoji Oshikata; Taiji Kawase; Etsuko Suzuki; Yukari Haramaki; Hideki Taniguchi
Journal:  Drug Metab Pharmacokinet       Date:  2013-10-29       Impact factor: 3.614

6.  Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients.

Authors:  C Dandara; C M Masimirembwa; A Magimba; J Sayi; S Kaaya; D K Sommers; J R Snyman; J A Hasler
Journal:  Eur J Clin Pharmacol       Date:  2001-04       Impact factor: 2.953

7.  Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions.

Authors:  R Scott Obach; Robert L Walsky; Karthik Venkatakrishnan
Journal:  Drug Metab Dispos       Date:  2006-11-08       Impact factor: 3.922

8.  A post-marketing observational study to assess the safety of mibefradil in the community in England.

Authors:  J Riley; L V Wilton; S A W Shakir
Journal:  Int J Clin Pharmacol Ther       Date:  2002-06       Impact factor: 1.366

Review 9.  Studying cytochrome P450 kinetics in drug metabolism.

Authors:  Melissa A Kramer; Timothy S Tracy
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-05       Impact factor: 4.481

10.  Prediction of drug-drug interactions based on time-dependent inhibition from high throughput screening of cytochrome P450 3A4 inhibition.

Authors:  Nobuo Sekiguchi; Atsuko Higashida; Motohiro Kato; Yoshiaki Nabuchi; Tetsuya Mitsui; Kenji Takanashi; Yoshinori Aso; Masaki Ishigai
Journal:  Drug Metab Pharmacokinet       Date:  2009       Impact factor: 3.614

View more
  4 in total

Review 1.  Critical evaluation of causality assessment of herb-drug interactions in patients.

Authors:  Charles Awortwe; Memela Makiwane; Helmuth Reuter; Christo Muller; Johan Louw; Bernd Rosenkranz
Journal:  Br J Clin Pharmacol       Date:  2018-01-29       Impact factor: 4.335

2.  Cytochrome P450 Enzyme Inhibition and Herb-Drug Interaction Potential of Medicinal Plant Extracts Used for Management of Diabetes in Nigeria.

Authors:  Ogochukwu Amaeze; Heather Eng; Lauren Horlbogen; Manthena V S Varma; Angela Slitt
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-05       Impact factor: 2.441

Review 3.  Cytochrome P450 and P-Glycoprotein-Mediated Interactions Involving African Herbs Indicated for Common Noncommunicable Diseases.

Authors:  Gregory Ondieki; Makafui Nyagblordzro; Siambi Kikete; Rongjia Liang; Lili Wang; Xin He
Journal:  Evid Based Complement Alternat Med       Date:  2017-01-31       Impact factor: 2.629

4.  Inhibitory Effects of Schisandra Lignans on Cytochrome P450s and Uridine 5'-Diphospho-Glucuronosyl Transferases in Human Liver Microsomes.

Authors:  Hyung-Ju Seo; Seung-Bae Ji; Sin-Eun Kim; Gyung-Min Lee; So-Young Park; Zhexue Wu; Dae Sik Jang; Kwang-Hyeon Liu
Journal:  Pharmaceutics       Date:  2021-03-10       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.